Objective: The aim of this study was to examine whether obesity modifies the effects of endogenous steroid sex hormones on arterial calcification in women at midlife.
T he incidence of coronary artery disease (CAD) increases after the fifth decade of life among women. 1 This suggests that alterations of steroid sex hormones (SSHs) around this age may play a key role in the development of the disease.
Obesity significantly influences the level of SSHs, 2 mainly after menopause. 3 Lower sex hormoneYbinding globulin (SHBG) and higher estrogen and androgen concentrations have been observed among obese postmenopausal compared with nonobese women. 4<6 Furthermore, obesity has been suggested to be related to CAD through its associations with several cardiovascular risk factors such as hypertension, lipid abnormalities, and impaired glucose metabolism. 7<10 Therefore, it is possible that the associations between SSHs and the development of CAD vary by obesity status.
Arterial calcification, a marker of calcified atheroma and total plaque burden, has been associated with an increase risk of CAD. 11 Few studies have evaluated the relationship between endogenous SSHs and arterial calcification in women. 12<14 Furthermore, the relationships between SSHs and CAD 12<15 are not completely clear. For testosterone (T), inconsistent findings have been reported with studies showing no relationship, 12, 14 a positive relationship (adverse effect), 15 or a negative relationship (protective effect) 13, 16, 17 with arterial calcification, 12<14 other subclinical measures, 14, 16, 17 or CAD 15 in young to middle-aged, 14 premenopausal, 16 or postmenopausal 12,13,15<17 women.
The effect of endogenous estrogen on CAD is also not clear. Although estrogen is widely regarded as protective against atherosclerosis, 18 no relationship was observed between endogenous estrogen and arterial calcification 12, 13 or CAD 19 in postmenopausal women.
The relationship between SHBG and CAD has not been well investigated. Low plasma levels of SHBG were found to be independently associated with CAD in women. 20 Recently, two studies have evaluated the association between SHBG and arterial calcification with conflicting findings. 13, 14 Results from the Multi-Ethnic Study of Atherosclerosis (MESA), among postmenopausal women aged 45 to 84 years, showed that higher coronary artery calcification (CAC) scores were associated with higher SHBG. 13 On the other hand, Calderon-Margalit et al 14 reported an inverse relationship between SHBG and the presence of CAC in young to middle-aged women.
Despite the well-known metabolic effect of obesity on SSHs 2,3 and the association of obesity measures with unfavorable CAD risk profiles, 7<10 none of the studies that evaluated the relationship between SSHs and arterial calcification 12<14 assessed the effect modification of obesity. To the best of our knowledge, only one study presented a stratification analysis for T and carotid atherosclerosis by obesity status in postmenopausal women. 17 A protective effect of T was observed in the nonobese group only. Therefore, the purpose of this study was to evaluate the cross-sectional effect of endogenous SSHs on the presence and extent of CAC and aortic calcification (AC) stratified by obesity in women at midlife. We hypothesized that the associations between SSHs and arterial calcification would vary by obesity status.
METHODS

Study population
The Study of Women's Health Across the Nation (SWAN) is a multiethnic longitudinal study, designed to examine the physical, biological, psychological, and social changes during the menopausal transition. The detailed study design for SWAN has been previously published. 21 Briefly, between 1996 and 1997, 3,302 participants aged 42 to 52 years were recruited from seven designated sites (Boston, MA; Detroit, MI; Oakland, CA; Los Angeles, CA; Pittsburgh, PA; Chicago, IL; and Newark, NJ).
The present study used the data from the SWAN Heart ancillary study, which was conducted at the Pittsburgh and Chicago sites to examine the natural history of subclinical CAD. Between 2001 and 2003 (coincident with the fourthseventh annual SWAN visits), 608 SWAN participants (382 white, 226 African American) were enrolled in the SWAN Heart ancillary study. SWAN participants were only eligible for the ancillary study if they had not had a hysterectomy or bilateral oophorectomy subsequent to their enrollment in the SWAN study, were not pregnant, were free of self-reported cardiovascular disease, were not diabetic, and did not report current hormone use.
At the Pittsburgh site only, limited SWAN Heart enrollment began before the fourth annual visit of SWAN. Those participants were deemed eligible for SWAN Heart if they were not pregnant at baseline even if they failed to meet the other eligibility criteria. Therefore, participants were excluded from the current analysis for the following reasons: 16 underwent hysterectomy, 65 reported using hormones, and 3 developed cardiovascular disease or diabetes. Data regarding body mass index (BMI) were missing in 25 participants who also were excluded from the analysis. Because of technical problems, 31 participants had no CAC and AC score, and 2 had no AC score. The final samples were 468 women for CAC outcomes and 466 for AC outcomes. Sample size in the analytic models varied based on missing data for SSHs (n = 27), low-density lipoprotein (LDL; n = 56), triglycerides (n = 53), and homeostatic model assessment of insulin resistance (HOMA index; n = 78). Participants who were not included in the analysis had lower T, higher SHBG, and lower free androgen index (FAI), waist circumference, weight, BMI, and systolic blood pressure than did those who were included. No significant differences were found between the two groups in age, race, CAC score, AC score, lipids, and HOMA index.
Research protocols were approved by the institutional review board at each site, and all the participants provided written informed consent before enrollment.
Study measures CAC and AC measures
CAC and AC were measured during the SWAN Heart baseline. Electron beam tomography studies were conducted using a GE-Imatron C-150 Ultrafast CT scanner (Imatron, South San Francisco, CA) administered by a trained technician. An initial scout scan was performed to identify anatomical landmarks. To evaluate the coronary arteries, 30 to 40 contiguous 3-mm-thick transverse images were obtained from the level of the aortic root to the apex of the heart during maximal breath-holding. To evaluate the aortic artery, 30 to 40 6-mm contiguous images were obtained from the aortic arch to the iliac bifurcation with a 300-millisecond exposure time. All scans were read at the University of Pittsburgh with a DICOM workstation and software by AcuImage, Inc (South San Francisco, CA) using the method of Agatston et al. 22 The presence of AC and/or CAC was determined in a given image if at least three contiguous pixels were present with more than 130 Hounsfield units. The CAC score was the sum of scores for each of the four major epicardial coronary arteries, whereas the AC was obtained from the single aortic score. The scoring system had a high reproducibility, with an intraclass correlation of 0.98 and 0.99 for aortic and coronary scores, respectively. 23 
Physical measures
Waist circumference, weight, and height were measured annually. BMI was calculated as weight (in kilograms) divided by height (in meters squared). BMI was categorized into two levels: BMI less than 30 kg/m 2 (nonobese) and BMI of 30 kg/m 2 or greater (obese). Blood pressure was measured in the right arm with the participant seated after at least 5 minutes of rest. The average of two sequential measures was used.
Blood assays
A fasting blood specimen was obtained during the early follicular phase of the menstrual cycle (days 2-5) if the participants were still menstruating. Participants were scheduled for venipuncture on days 2 to 5 of a spontaneous menstrual cycle occurring within 60 days of recruitment. Two attempts were made to obtain the days 2 to 5 sample; however, if a timed sample could not be obtained (as was especially the case for late perimenopausal and postmenopausal women), a random fasting sample was taken within the 90-day period of recruitment. Hormone assays were performed at the University of Michigan SWAN Endocrine Laboratory with the ACS-180 automated analyzer (Bayer Diagnostics Corp., Norwood, MA). Estradiol (E 2 ) was measured using a modified, offline ACS-180 (E 2 -6), with a lower limit of detection of 1.0 pg/mL, and interassay and intra-assay coefficients of variation averaged 10.6% and 6.4%, respectively. The serum T concentration was evaluated with the ACS-180 total T assay modified to increase precision in the low ranges, with a lower limit of detection of 2 ng/dL and interassay and intra-assay coefficients of variation of 10.5% and 8.5%, respectively. SHBG was measured with a two-site chemiluminescent immunoassay, with a lower limit of detection of 1.95 nmol/L and interassay and intra-assay coefficients of variation of 9.9% and 6.1%, respectively. E 2 assays were conducted in duplicate, whereas T and SHBG assays were conducted in singular. The arithmetic mean for the duplicate measures was calculated and reported (coefficient of variation of 3%-12%). FAI was used to estimate the amount of the free active (unbounded to SHBG) T. FAI was calculated as (100 Â T)/ (28.84 Â SHBG). 24 Hormone values below the lower limit of detection were replaced with a random value between zero and the lower limit of detection. Cycle day of blood draw was reported as during days 2 to 5 (for regularly menstruating women) or outside of that period (for irregularly menstruating and for nonmenstruating women).
Lipids, glucose, and insulin were assayed at the Medical Research Laboratories (Lexington, KY), certified by the National Heart, Lung, and Blood Institute, Centers for Disease Control and Prevention Part III program. 25 Total cholesterol and triglyceride levels were analyzed using enzymatic methods on a Hitachi 747 analyzer (Boehringer Mannheim Diagnostics, Indianapolis, IN), 26 and high-density lipoprotein (HDL) was isolated using heparin-manganese. 27 LDL was calculated using the Friedewald equation. 28 Serum insulin was measured by a radioimmunoassay (Diagnostic Products Corporation, Coat-a-Count) procedure and monitored as part of the monthly quality assurance program by the Diabetes Diagnostic Laboratory at the University of Missouri. Glucose was measured with a hexokinase-coupled reaction (Boehringer Mannheim Diagnostics). The HOMA index was calculated from fasting insulin and glucose as (insulin [in milliunits per liter] Â glucose [in millimoles per liter])/22.5. 29, 30 
Menopause status
Menopause status was defined as follows: (1) premenopausal: menstrual period in the past 3 months with no change in regularity in the past 12 months; (2) early perimenopausal: menstrual period in the past 3 months with some change in regularity during the previous 12 months; (3) late perimenopausal: no menstrual period within the past 3 months, but some menstrual bleeding over the previous 12 months; and (4) postmenopausal: no menstrual period within the past 12 months. Both early perimenopausal and late perimenopausal categories were collapsed for this analysis to maintain sufficient number in each category.
Statistical analysis
CAC and AC scores were right skewed because many participants had zero values (CAC: 52.3%, AC: 29.8%). To use all available data, each of the CAC and AC scores was analyzed as both categorical (presence of calcification) and continuous (extent of calcification) outcomes. 13 Presence of calcification was a two-level variable: none, if Agatston score is 0, and any, if Agatston score is higher than 0. Extent of calcification was the log transformation of nonzero Agatston scores.
Descriptive statistics were performed to summarize study variables by BMI groups. The differences between BMI groups in study variables were assessed using the Wilcoxon rank-sum test and W 2 test as appropriate. Data are presented as median/interquartile ranges or percentages.
Univariate and multivariable analyses were performed for the total sample and stratified by BMI groups. Logistic regression was used for the presence of calcification outcomes, and linear regression was used for the extent of calcification outcomes. SSHs, triglycerides, insulin, glucose, and HOMA index were log transformed in univariate and multivariable linear regression because their original distributions were not normal. Standardized estimates are presented for linear regression to facilitate the interpretation of the estimated coefficients. Odds ratios are presented per 1-SD change of hormones.
For multivariable analyses, all variables found to be significantly associated with study outcomes in the univariate analyses were considered as potential covariates. Age, race, study site, cycle day, waist circumference, and systolic blood pressure were included in all models (models 1 and 2). Lipid/ lipoprotein measures and glucose metabolism measures were added to the final models (model 2) to assess the impact of these variables on the associations between SSHs and study outcomes. Because these measures were highly correlated, only covariates that were found to affect the regression coefficient by 15% or more were included in the final models. Both variance inflation factor and condition index were used to test for multicollinearity.
All final models were refitted, including all potential covariates found to be significantly associated with study outcomes in univariate analyses but did not change the regression coefficient by 15% or more (data not shown). Similar results were obtained. Only parsimonious models are presented.
Effect modifications by BMI groups were evaluated for all SSHs in models before stratification.
All analyses were performed with SAS version 9.2 (SAS Institute, Cary, NC) and STATA version 10 (StataCorp., College Station, TX) and were two sided at > = 0.05.
RESULTS
Baseline characteristics and potential covariates
Characteristics of the study population are presented in Table 1 . Obese participants had a worse cardiovascular risk profile in comparison with nonobese participants. SSHs significantly differed by BMI; in obese participants, androgens were significantly higher, whereas SHBG was significantly lower compared with nonobese participants. In Figure 1 , the prevalence of CAC and AC was significantly higher in the obese compared with nonobese group. Furthermore, a greater extent of AC was found in obese in comparison to nonobese women (median score, 46.5 vs 19.0, respectively; P = 0.001). A similar pattern was seen for the extent of CAC; however, it was not significant (median score, 8.2 vs 6.7, respectively; P = 0.3).
Age, body composition measures, triglycerides, LDL, HOMA index, and systolic blood pressure were significantly associated with calcification outcomes in univariate analyses. Being postmenopausal was associated with a greater extent of CAC but not AC in comparison with premenopausal women (data not shown).
Presence of CAC and AC
In unadjusted analyses of the total group, higher E 2 (odds ratio [OR], 0.78; 95% CI, 0.63-0.96, for each 1-SD greater E 2 ) and higher SHBG (OR, 0.66; 95% CI, 0.53-0.81, for each 1-SD greater SHBG) were associated with lower odds of CAC. These associations did not persist with multivariable adjustment either before or after stratification by BMI.
In unadjusted analyses of the total group, higher E 2 (OR, 0.82; 95% CI, 0.68-0.99, for each 1-SD greater E 2 ) was associated with lower odds of AC, and higher T (OR, 1.26; 95% CI, 1.01-1.57, for each 1-SD greater T) was associated with higher odds of AC. These associations turned out to be not significant, with further adjustment either before or after stratification by BMI.
SHBG was not associated with the presence of AC in univariate analysis. After adjusting for potential covariates (model 2), SHBG was positively associated with the presence of AC among the nonobese group (OR, 1.64; 95% CI, 1.16-2.32, for each 1-SD greater SHBG). The same results were obtained after including menopause status in the final models (data not shown). We were not able to study the same association among the obese participants because only six of them had no AC, and, therefore, the models would not converge (data not shown). Table 2 shows results for the extent of CAC. In the univariate analysis, E 2 had a significant negative association with the extent of CAC only among the obese group (A = j0.220, P = 0.008). In addition, an increase in SHBG was associated with a greater extent of CAC among nonobese (A = 0.285, P = 0.02) and a lesser extent of CAC among obese participants (A = j0.205, P = 0.01). In adjusted analysis, the association between E 2 and the extent of CAC significantly differed by obesity status (P interaction = 0.03), as seen in model 1. High E 2 was significantly associated with less extent of CAC among obese participants (A = j0.193, P = 0.02). This negative association among obese women was attenuated with further adjustment (P = 0.08), as seen in model 2. Significant interactions between obesity and both SHBG (P G 0.001) and FAI (P = 0.02) were found in relation to the extent of CAC ( Figs. 2 and 3 , respectively). High SHBG was associated with a greater extent of CAC in nonobese participants (A = 0.355, P = 0.003) and a lesser extent of CAC among obese participants (A = j0.175, P = 0.03; Fig. 2) . These associations remained significant in the final models.
Extent of CAC and AC
In Figure 3 , FAI was negatively associated with the extent of CAC in the nonobese group (A = j0.255, P = 0.04; Table 2 , model 1), whereas no significant association was seen in the obese group. These associations persisted in the final models (Table 2, model 2). Similar results were observed in models that included menopause status (data not shown).
When AC was evaluated, a similar significant interaction between SHBG and obesity was observed (P interaction = 0.03; Table 3 , model 2). SHBG was positively associated with the extent of AC in the final model.
DISCUSSION
Our results provide clear evidence for the importance of considering obesity status when the associations between SSHs and arterial calcification are assessed. The relationship between CAC and both SHBG and FAI was significantly different by obesity status independent of the other well-known risk factors. A higher SHBG was associated with less calcification in the obese group and with more calcification in the nonobese group. In addition, an increase in FAI was associated with less calcification in the nonobese group. No significant association was observed for FAI in the obese group.
In women, conflicting findings have been reported regarding the potential role of androgens as CAD risk factors. In a study that included postmenopausal women undergoing coronary angiography, free T was positively associated with severity of CAD. 15 On the other hand, higher but physiological levels of androgens were found to be correlated with lower risk of carotid artery disease in premenopausal and postmenopausal women. 16 Lower levels of T and free T index were reported among women with CAD compared with those without. 31 Moreover, findings from MESA supported an independent negative association between free T and the extent of CAC in postmenopausal women. 13 A recent report from a prospective Rancho Bernardo study in postmenopausal women concluded that low levels of T are associated with an increased risk of coronary heart disease events. 32 In addition, very recent results from a prospective cohort European study in women aged 57.9 T 14.4 years showed that low baseline T was associated with increased all-cause mortality and incident cardiovascular events independent of traditional risk factors. 33 Our finding of a negative association between FAI and CAC among nonobese women is consistent with the results from MESA 13 and other studies. 16,17,31<33 Interestingly, in nonobese postmenopausal women, the prevalence of carotid atherosclerosis was significantly higher with a low T level. 17 Because obesity has a substantial impact on cardiovascular risk profile, 7<10 it is possible that the mechanism by which T affects CAD will not be the same in nonobese compared with obese women. The relationships between androgens and CAD are complex and not completely understood. T provides an antiatherogenic effect by stimulating efflux of cellular cholesterol to HDL and proatherogenic effects by facilitating the uptake of lipoproteins. 34, 35 T affects cardiovascular risk factors by decreasing the serum levels of HDL, plasminogen activator type 1 (deleterious), lipoprotein(a), fibrinogen, insulin, and leptin (beneficial). 36, 37 Moreover, T inhibits the calcium channel of smooth muscle cells and suppresses the activation of proinflammatory cytokines. 36, 37 Therefore, it is possible that FAI was associated with a lesser extent of calcification in healthy nonobese women through the above suggested favorable mechanisms. 37 Our results showed different patterns of associations between SHBG and arterial calcification by obesity status. The positive association between SHBG and the extent of calcification among the nonobese group was consistent with other researchers. 13 In a sample of postmenopausal women (BMI grand mean [SD]: 28.3 [5.33]) who were not taking hormone therapy or using insulin, greater SHBG was associated with a greater extent of calcification (A = 0.298, P = 0.03; both SHBG and extent of calcification scores were log transformed) in a full-adjusted model. 13 SHBG is a glycoprotein synthesized in the liver and binds with higher affinity to androgens more than to estrogens. 25 An increase in SHBG is associated with a decreased androgenic status. Therefore, one could argue that the positive association that we reported may be explained by the direct relationship between SHBG and androgen. However, including both T and SHBG in the same model (data not shown) did not attenuate the significant positive effect of SHBG on the extent of CAC among nonobese women. Probably, there are other pathways by which SHBG affects calcification that we do not know. SHBG may have biological functions beyond simple regulation of the levels of free sex hormones. It has been reported that SHBG is part of a signal transduction system for steroids at the cell membrane. 38 Further studies are needed to understand the mechanism of this positive association that we and others 13 observed.
The negative relationship between SHBG and calcification among the obese group could be explained by its association with androgens. When both T and SHBG are included in the model for the obese group, the negative relationship between SHBG and extent of CAC was no longer significant (data not shown). Higher SHBG is associated with higher HDL levels. 12, 39 Increasing levels of HDL are associated with less subclinical atherosclerosis. 12 Hepatic lipase, involved in HDL catabolism, is known to be stimulated by androgens independently of insulin and abdominal fat. Therefore, high SHBG would result in low free androgen, which maintains a low hepatic lipase activity and a high level of HDL. 39 In this study, none of the SSHs were associated with the presence of CAC in the final models. Our results were similar to those of Ouyang et al, 13 who reported the null effects of SSHs on the presence of CAC among a multiethnic sample of postmenopausal women. In contrast, Calderon-Margalit et al 14 reported a prospective significant inverse association between SHBG and the presence of CAC among young to middle-aged women (OR for women with SHBG above the median, 0.59; 95% CI, 0.4-0.87; P = 0.008). The inconsistency between our findings and those of Calderon-Margalit et al could be related to differences in study design (prospective vs cross-sectional) and the study population's menopause status. It is also possible that we did not find any significant association between SSHs and presence of CAC because of the lack of sufficient power when evaluating the outcome variable as a binary variable (presence of CAC) given our small sample size. Despite the well-known advantages of dichotomizing a continuous variable, one main disadvantage is the loss of power. 40 The main limitations of the current study include the following: (1) the cross-sectional design, which limited any causal inference. A second measure for calcification is now available within SWAN and can be used for a longitudinal assessment. (2) Hormone assays were collected during the early follicular phase of the menstrual cycle, which might not be optimum for all hormones that were measured. All our analyses were adjusted for cycle day. (3) Biologically active T was not measured directly. However, our estimation of FAI is a valid measure of free T. 41 (4) Obese participants' scans may have more artifact than nonobese participants that artificially raised the calcium scores. This is very difficult to control for and still under investigations. 42 The main strengths of our study are as follows: (1) the first to consider evaluating the roles of SSHs on arterial calcification by obesity status; (2) the study population being wellcharacterized women followed throughout the menopausal transition; and (3) current analysis adjusted for most of the major and potential covariates that may impact the assessed associations.
CONCLUSIONS
In conclusion, our findings suggested that obesity may have significant impact on how SSHs are associated with arterial calcifications. Both SHBG and FAI are strongly associated with the extent of CAC. The directions of these associations significantly differed by obesity status. These data may explain why the results from previous reports are inconsistent. Future studies of SSHs and other subclinical measures should consider assessing effect modification by BMI.
